Terns Pharmaceuticals Relocates Principal Executive Offices
Ticker: TERN · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1831363
Sentiment: neutral
Topics: corporate-actions, filing-update
TL;DR
Terns Pharma moved its HQ to Foster City, CA effective Nov 14.
AI Summary
Terns Pharmaceuticals, Inc. announced on November 14, 2024, a change in its principal executive offices to 1065 East Hillsdale Blvd., Suite 100, Foster City, California. This move is effective as of November 14, 2024. The company also filed its 8-K report on November 18, 2024, detailing this change and other corporate information.
Why It Matters
A change in principal executive offices can indicate growth, consolidation, or strategic shifts for a company. Investors should monitor if this move impacts operations or costs.
Risk Assessment
Risk Level: low — The filing solely reports a change in the company's principal executive office address, which is a routine administrative update.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- November 14, 2024 (date) — Effective date of office change
- November 18, 2024 (date) — Filing date of 8-K
- 1065 East Hillsdale Blvd., Suite 100, Foster City, California (location) — New principal executive offices
FAQ
What is the new address for Terns Pharmaceuticals, Inc.'s principal executive offices?
The new address is 1065 East Hillsdale Blvd., Suite 100, Foster City, California.
When was the change in principal executive offices effective?
The change was effective as of November 14, 2024.
On what date was this 8-K filing submitted?
The 8-K filing was submitted on November 18, 2024.
What is the state of incorporation for Terns Pharmaceuticals, Inc.?
The state of incorporation is Delaware.
What is the SIC code for Terns Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-11-18 16:15:11
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
Filing Documents
- tern-20241114.htm (8-K) — 46KB
- tern-ex99_1.htm (EX-99.1) — 15KB
- img52906712_0.jpg (GRAPHIC) — 31KB
- 0000950170-24-127964.txt ( ) — 227KB
- tern-20241114.xsd (EX-101.SCH) — 26KB
- tern-20241114_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 18, 2024, the Company issued a press release announcing the appointment of Ms. Turner to the Board and the resignation of Dr. Taylor. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Terns Pharmaceuticals, Inc. on November 18, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: November 18, 2024 By: /s/ Amy Burroughs Amy Burroughs Chief Executive Officer